Streetbeat News

Price Targets

LSEA

B. Riley Securities analyst Alex Rygiel maintains a Buy rating on Landsea Homes (NASDAQ:LSEA) and raises the price target from $10 to $12.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:33 pm

BALL

Wells Fargo analyst Gabe Hajde has upgraded Ball Corporation (NYSE: BALL) from Underweight to Equal-Weight and raised the price target from $52 to $55.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 12:32 pm

BALL

Wells Fargo analyst Gabe Hajde has upgraded Ball Corporation (NYSE: BALL) from Underweight to Equal-Weight and announced a $55 price target.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 12:32 pm

HCC

B. Riley Securities analyst Lucas Pipes has reiterated a Buy rating on Warrior Met Coal (NYSE:HCC) and maintained a $58 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:26 pm

ATMU

Wells Fargo analyst Joseph O'Dea initiates coverage on Atmus Filtration Techs (NYSE:ATMU) with an Overweight rating and a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 12:26 pm

LSPD

Stifel analyst Suthan Sukumar maintains a Hold rating on Lightspeed Commerce (NYSE:LSPD) and raises the price target from $16 to $18.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:20 pm

ZS

JMP Securities analyst Trevor Walsh reiterated a Market Outperform rating on Zscaler (NASDAQ:ZS) and maintained a $225 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:18 pm

ATLC

JMP Securities analyst David Scharf maintains a Market Outperform rating on Atlanticus Holdings (NASDAQ:ATLC) and raises the price target from $39 to $48.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:17 pm

HOTH

Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Hoth Therapeutics (NASDAQ:HOTH) and maintains a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:17 pm

UNCY

Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintains a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 12:14 pm